Docstoc

Agenda

Document Sample
Agenda Powered By Docstoc
					Ce dossier est destiné exclusivement à usage privé, suivant l'article L.122-5 du code de la propriété intellectuelle.
Quelque autre utilisation que ce soit est formellement interdite. Sont également interdits le prêt, la duplication et la
copie partielle ou totale de ce dossier Tous les droits de cette oeuvre sont réservés
Comité d‘éthique en recherche médicale et en
santé
                      Ermes




                                                                               Sommaire
Agenda ................................................................................................................................................................... 2
    "Le développement durable, l'éthique et l'éducation à l'horizon 2020 : quels défis pour la Biologie ?" 2
Recherche .............................................................................................................................................................. 3
    Le ministre autrichien s'engage à accorder des fonds supplémentaires à la recherche fondamentale 3
    Congress Passes Massive Measure to Support Research, Education ...................................................... 3
    The Cha-Cha-Cha Theory of Scientific Discovery ....................................................................................... 3
Recherche clinique ................................................................................................................................................ 3
    Ethics & Clinical Trials: Debate hots up again ............................................................................................ 3
    Assessing research risks systematically: the net risks test ...................................................................... 4
    Refuting the net risks test: a response to Wendler and Miller’s "Assessing research risks
    systematically" ............................................................................................................................................... 4
    Board games ................................................................................................................................................... 4
    Human-subjects research: Trial and error ................................................................................................... 4
    GUIDELINE ON STRATEGIES TO IDENTIFY AND MITIGATE RISKS FOR FIRST-INHUMAN CLINICAL
    TRIALS WITH INVESTIGATIONAL MEDICINAL PRODUCTS ....................................................................... 5
    The Sydney Declaration: Good Research Drives Good Policy and Programming .................................. 5
    Growth hormone can add 3 inches to short kids ........................................................................................ 5
    South Africa's Experience of the Closure of the Cellulose Sulphate Microbicide Trial ........................... 5
    Feud Over AIDS Vaccine Trials Leads Prominent Italian Researchers to Court ...................................... 5
    Why do collaborative research? ................................................................................................................... 6
Cellules souches, clonage, recherche sur l’embryon ........................................................................................ 6
    Danforth used disingenuous language to advance embryonic stem cell research agenda .................... 6
    A Scientist's View of the Ethics of Human Embryonic Stem Cell Research ............................................. 6
    Does Government Regulation Inhibit Embryonic Stem Cell Research and Can It Be Effective? ............ 6
 Europe................................................................................................................................................................. 7
    Joint Statement .............................................................................................................................................. 7
 Etats-Unis ........................................................................................................................................................... 7
    Future of Stem Cell Tests May Hang on Defining Embryo Harm ............................................................... 7
    Stem cell dissent roils states ........................................................................................................................ 7
    For Missouri, Stem Cell Amendment Changes Little .................................................................................. 7
 Royaume Uni ...................................................................................................................................................... 7
    The Human Tissue and Embryos Bill: a chance for further debate ........................................................... 7
    Parliamentary Joint Select Committee report on Human Tissue and Embryos (Draft) Bill ..................... 8
    Response to HFEA consultation on human-animal embryos in research ................................................ 8
    Joint committee report on human tissues and embryos - faint praise but mostly huge disappointment
     ......................................................................................................................................................................... 8
    Parliamentary committee recommends sweeping changes to the Human Tissue and Embryos (Draft)
    Bill .................................................................................................................................................................... 8
    Animal-human chimeras: Summary of UK Academy of Medical Sciences Report................................... 8
 Espagne .............................................................................................................................................................. 9
    Spanish Stem Cell Bank Interviews Examine the Interest of Couples in Donating Surplus Human IVF
    Embryos for Stem Cell Research .................................................................................................................. 9
 Corée ................................................................................................................................................................... 9
    Recombination Signatures Distinguish Embryonic Stem Cells Derived by Parthenogenesis and
    Somatic Cell Nuclear Transfer ...................................................................................................................... 9
    Clonage humain : l'affaire Hwang élucidée ................................................................................................ 10
    Fabricated stem cell line origin revealed ................................................................................................... 10
 Australie............................................................................................................................................................ 10
    NSW offers $500,000 for stem cell breakthrough ...................................................................................... 10
 Japon ................................................................................................................................................................ 11
    Irrational Japanese regulations hinder human embryonic stem cell research ....................................... 11
Génétique, OGM .................................................................................................................................................. 11
    Death Points to Risks in Research ............................................................................................................. 11
    Gene therapy trial on hold ........................................................................................................................... 11
    Death Prompts a Review of Gene Therapy Vector .................................................................................... 12
    Speculation on gene therapy trial death 'premature' ................................................................................ 12
    Cancer Test Dispute Pits Researcher Against a Firm She Helped Create .............................................. 12
    Identifiability in Genomic Research ............................................................................................................ 12



Bénédicte de Boischevalier                                            envoi du 10 août 2007                                                                              -1-
Ce dossier est destiné exclusivement à usage privé, suivant l'article L.122-5 du code de la propriété intellectuelle.
Quelque autre utilisation que ce soit est formellement interdite. Sont également interdits le prêt, la duplication et la
copie partielle ou totale de ce dossier Tous les droits de cette oeuvre sont réservés
    US genetics bill blocked again .................................................................................................................... 12
    Targeted Genetics drug puts clinical trials in spotlight ............................................................................ 13
Pharmacogénétique ............................................................................................................................................ 13
    More-Accurate Cancer Treatment ............................................................................................................... 13
    Getting personal ........................................................................................................................................... 13
    Race in a Bottle ............................................................................................................................................ 13
    Personalized medicine takes a (tiny) step forward.................................................................................... 13
Biobanque ............................................................................................................................................................ 14
    Umbilical Cord Blood Bill Passed Into Law ............................................................................................... 14
Neurosciences ..................................................................................................................................................... 14
    La machine qui détecte la personnalité ...................................................................................................... 14
Médicaments, industrie pharmaceutique .......................................................................................................... 14
Pays en développement ...................................................................................................................................... 14
    Europe's clinical trials partnership programme in peril............................................................................ 14
    ATELIER INTERNATIONAL: "L'ETHIQUE DE LA RECHERCHE EN SANTE DANS LES PAYS DU SUD.
    PARIS 2007" .................................................................................................................................................. 14
Nanotechnologies ............................................................................................................................................... 16
    Nanotechnologies, Ethics and Politics ....................................................................................................... 16
Expérimentation animale .................................................................................................................................... 16
    Un groupe d'éthique lance une consultation sur le clonage animal à des fins d'approvisionnement
    alimentaire .................................................................................................................................................... 16
    COMMISSION RECOMMENDATION of 18 June 2007 on guidelines for the accommodation and care of
    animals used for experimental and other scientific .................................................................................. 16
Intégrité scientifique ........................................................................................................................................... 16
    Former UPenn postdoc faked images ........................................................................................................ 16
Ethique ................................................................................................................................................................. 17
    Lutter contre la maladie d'Alzheimer, c'est une urgence démocratique. ................................................ 17
    S Korea's code of ethics for robots ............................................................................................................ 17
Traitement compassionnel ................................................................................................................................. 17
    Court Rules Out Terminally Ill for Tests ..................................................................................................... 17
    Court Rejects the Right to Use Drugs Being Tested ................................................................................. 17
Publication, open access .................................................................................................................................... 18
    Reviewing Peer Review: NIH needs your help! .......................................................................................... 18
    Special feature: How should scientists sell science? ............................................................................... 18
    U.S. Output Flattens, and NSF Wonders Why............................................................................................ 18
    Ethics of guidelines for reviewers of medical manuscripts ..................................................................... 18
    Peer review as professional responsibility: A quality control system only as good as the participants
     ....................................................................................................................................................................... 19
    Yale dumps BioMedCentral ......................................................................................................................... 19
    The Dangers of Advocacy in Science ......................................................................................................... 19
Divers.................................................................................................................................................................... 19
    Has the Spread of HPV Vaccine Marketing Conveyed Immunity to Common Sense? ........................... 20

Agenda
Chers Collègues
Au nom de l'International Union of Biological Sciences et de sa Commission
Éducation, du Comité d'Organisation et de son secrétaire general, je suis
heureux de vous annoncer la tenue de BioEd 2008 en Bourgogne (France) du 24 au
28 juin. Le theme sera :
"Le développement durable, l'éthique et l'éducation à l'horizon 2020 : quels défis pour la
Biologie ?"
Dans la suite de BioEd 2000 à Paris (Muséum national d'histoire naturelle) et de
BioEd 2004 à Rio de Janeiro (Fondation Oswaldo Cruz), BioEd 2008 en Bourgogne
souhaite aborder ces questionnements à partir de contributions provenant aussi
bien du monde de l'éducation que de celui de la médiation, du monde de
l'entreprise comme celui de l'université, du monde des ONG comme celui des
collectivités territoriales.
En attaché à ce courrier électronique, vous trouverez la plaquette de
presentation de BioEd 2008, les formulaires d'inscription et de proposition de
contributions. Si vous avez besoin d'information complémentaire, contactez
Daniel Raichvarg (daniel.raichvarg@u-bourgogne.fr) ou 00 33 6 07 63 33 01
(mobile)..
Dans l'attente de vous recevoir en Bourgogne
Daniel RAICHVARG
Professor at University of Burgundy,
University Vice-President of Cultural Affairs,



Bénédicte de Boischevalier                                            envoi du 10 août 2007                                                                             -2-
Ce dossier est destiné exclusivement à usage privé, suivant l'article L.122-5 du code de la propriété intellectuelle.
Quelque autre utilisation que ce soit est formellement interdite. Sont également interdits le prêt, la duplication et la
copie partielle ou totale de ce dossier Tous les droits de cette oeuvre sont réservés
Director of CIMEOS (Science of Information and Communication
Research Laboratory)
Organizing Committee
André GIORDAN, President of the Education Commission of IUBS
Daniel RAICHVARG, General secretary of the BioEd 2008
Talal YOUNÈS, Executive Director of IUBS

Recherche
Source Cordis 07/08/2007
URL http://cordis.europa.eu/fetch?CALLER=FR_NEWS&ACTION=D&&SESSION=&&&RCN=28172
Le ministre autrichien s'engage à accorder des fonds supplémentaires à la recherche
fondamentale
[Date: 2007-08-07]
Lors de la présentation au Parlement national du rapport annuel du pays concernant la recherche et la
technologie, le Ministre autrichien de la recherche Johannes Hahn s'est engagé à investir davantage de fonds
publics dans la recherche fondamentale.
«Un budget plus important pour la recherche profitera nécessairement à la recherche fondamentale», a déclaré le
Ministre.
L'intégralité du rapport peut être consultée à l'adresse suivante:
http://www.bmvit.gv.at/service/publikationen/innovation/technologieberichte/ft_bericht07.html

Source Science 10 August 2007: Vol. 317. no. 5839, pp. 736 - 737
DOI: 10.1126/science.317.5839.736
URL http://www.sciencemag.org.gate2.inist.fr/cgi/reprint/317/5839/736.pdf
News of the Week
U.S. SCIENCE POLICY:
Congress Passes Massive Measure to Support Research, Education
Jeffrey Mervis
In 2005, a U.S. National Academies' panel drew up a blueprint for sustaining economic growth by strengthening
the country's research and educational systems (Science, 21 October 2005, p. 423). Last week, Congress
adopted nearly all of its recommendations in a bill that prescribes new policies and programs at six federal
agencies.

Source Science 10 August 2007: Vol. 317. no. 5839, pp. 761 - 762
DOI: 10.1126/science.1147166
URL http://www.sciencemag.org.gate2.inist.fr/cgi/reprint/317/5839/761.pdf
Perspectives
PHILOSOPHY OF SCIENCE:
The Cha-Cha-Cha Theory of Scientific Discovery
Daniel E. Koshland Jr.*
Scientific discoveries are the steps--some small, some big--on the staircase called progress, which has led to a
better life for the citizens of the world. Each scientific discovery is made possible by the arrangement of neurons
in the brain of one individual and as such is idiosyncratic. In looking back on centuries of scientific discoveries,
however, a pattern emerges which suggests that they fall into three categories--Charge, Challenge, and Chance--
that combine into a "Cha-Cha-Cha" Theory of Scientific Discovery. (Nonscientific discoveries can be categorized
similarly.)

Recherche clinique

Source The Economic Times India 30/07/2007
URL
http://economictimes.indiatimes.com/News/News_By_Industry/Healthcare__Biotech/Pharmaceuticals/Ethics__Cli
nical_Trials_Debate_hots_up_again/articleshow/2243281.cms
Ethics & Clinical Trials: Debate hots up again
30 Jul, 2007, 0508 hrs IST,KG Narendranath, TNN
NEW DELHI: The horrid theory of Indians as guinea pigs for the Big Pharma is up for debate again. As per news
reports independently confirmed by ET, the country‘s highest technical body for drugs — Drugs Technical
Advisory Board (DTAB) — has decided to propose to the government a key change in regulation of clinical trials.
It favoured allowing first-stage clinical trials of drug molecules discovered abroad in India, concurrently with first-
time conduct of such trials abroad. DTAB‘s advice would weigh heavily on the government, although given the
contentious nature of the issue, the political establishment could still dither.

Source Journal of Medical Ethics 2007;33:481-486; doi:10.1136/jme.2005.014043
URL http://jme.bmj.com.gate2.inist.fr/cgi/reprint/33/8/481
Research risks



Bénédicte de Boischevalier                      envoi du 10 août 2007                                               -3-
Ce dossier est destiné exclusivement à usage privé, suivant l'article L.122-5 du code de la propriété intellectuelle.
Quelque autre utilisation que ce soit est formellement interdite. Sont également interdits le prêt, la duplication et la
copie partielle ou totale de ce dossier Tous les droits de cette oeuvre sont réservés
Assessing research risks systematically: the net risks test
D Wendler and F G Miller
Department of Clinical Bioethics, The NIH Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
Correspondence to:
D Wendler
Building 10, Room 1C118, NIH, Bethesda, MD 20892, USA; dwendler@nih.gov
Original version received 22 August 2005
Revised version received 19 December 2005
Accepted for publication 27 December 2005
--------------------------------------------------------------------------------
Dual-track assessment directs research ethics committees (RECs) to assess the risks of research interventions
based on the unclear distinction between therapeutic and non-therapeutic interventions. The net risks test, in
contrast, relies on the clinically familiar method of assessing the risks and benefits of interventions in comparison
to the available alternatives and also focuses attention of the RECs on the central challenge of protecting
research participants.

Source Journal of Medical Ethics 2007;33:487-490; doi:10.1136/jme.2006.016444
URL http://jme.bmj.com.gate2.inist.fr/cgi/reprint/33/8/487
Refuting the net risks test: a response to Wendler and Miller’s "Assessing research risks
systematically"
C Weijer1 and P B Miller2
1 Department of Philosophy, Talbot College, University of Western Ontario, London, Ontario, Canada
2 Department of Philosophy, University of Toronto, Toronto, Ontario, Canada
Correspondence to:
Charles Weijer
Department of Philosophy, Talbot College, University of Western Ontario, London, Ontario, Canada, N6A 3K7;
charles.weijer@dal.ca
Original version received 18 July 2006
Revised version received 3 October 2006
Accepted for publication 6 October 2006
   ABSTRACT
Earlier in the pages of this journal (p 481), Wendler and Miller offered the "net risks test" as an alternative
approach to the ethical analysis of benefits and harms in research. They have been vocal critics of the dominant
view of benefit–harm analysis in research ethics, which encompasses core concepts of duty of care, clinical
equipoise and component analysis. They had been challenged to come up with a viable alternative to component
analysis which meets five criteria. The alternative must (1) protect research subjects; (2) allow clinical research to
proceed; (3) explain how physicians may offer trial enrolment to their patients; (4) address the challenges posed
by research containing a mixture of interventions and (5) define ethical standards according to which the risks and
potential benefits of research may be consistently evaluated. This response argues that the net risks test meets
none of these criteria and concludes that it is not a viable alternative to component analysis.
--------------------------------------------------------------------------------
Keywords: benefit-harm analysis; clinical research; component analysis; research ethics; research ethics
committee

Source Nature 448, 511-512 (2 August 2007) | doi:10.1038/448511b; Published online 1 August 2007
URL http://www.nature.com.gate2.inist.fr/nature/journal/v448/n7153/pdf/448511b.pdf
Board games
Abstract The way research on human subjects is overseen in the United States requires reform.
There is no greater burden of responsibility for scientists than that placed on those who conduct medical research
on human subjects. On the rare occasions that this duty is inappropriately discharged, the results can be
devastating. Even so, once the initial outcry dies down, little tends to change.

Source Nature 448, 530-532 (2 August 2007) | doi:10.1038/448530a; Published online 1 August 2007
URL http://www.nature.com.gate2.inist.fr/nature/journal/v448/n7153/pdf/448530a.pdf
Human-subjects research: Trial and error
Heidi Ledford1
Heidi Ledford writes for Nature from Boston, Massachusetts.
Abstract The ethics committees that oversee research done in humans have been attacked from all sides. Heidi
Ledford recounts the struggle to come up with alternatives.
D. PARKINS
Fourteen years of treating people with tuberculosis has taught physician William Burman what to expect when a
patient walks through his door. Tuberculosis is not typically a disease of the well-heeled. Many patients in the
United States are foreign born. English is their second language. Fewer than half have completed a high-school
education, and many have spent time in jails or homeless shelters.

Source EMEA 19/07/2007
URL http://www.emea.europa.eu/pdfs/human/swp/29464807en.pdf



Bénédicte de Boischevalier                      envoi du 10 août 2007                                               -4-
Ce dossier est destiné exclusivement à usage privé, suivant l'article L.122-5 du code de la propriété intellectuelle.
Quelque autre utilisation que ce soit est formellement interdite. Sont également interdits le prêt, la duplication et la
copie partielle ou totale de ce dossier Tous les droits de cette oeuvre sont réservés
GUIDELINE ON STRATEGIES TO IDENTIFY AND MITIGATE RISKS FOR FIRST-INHUMAN
CLINICAL TRIALS WITH INVESTIGATIONAL MEDICINAL PRODUCTS
EXECUTIVE SUMMARY
This guideline is intended to assist sponsors in the transition from non-clinical to early clinical
development. It identifies factors influencing risk for new investigational medicinal products and
considers quality aspects, non-clinical and clinical testing strategies and designs for first-in-human
clinical trials. Strategies for mitigating and managing risk are given, including the calculation of the
initial dose to be used in humans, the subsequent dose escalation, and the conduct of the clinical trial.

Source International AIDS Society 07/2007
URL http://www.iasociety.org/Default.aspx?pageId=63
The Sydney Declaration: Good Research Drives Good Policy and Programming
- A Call to Scale Up Research
4th IAS Conference on Pathogenesis, Treatment and Prevention
22 – 25 July 2007
Sydney, Australia
Ten per cent of all resources dedicated to HIV programming should be used for research towards optimizing
interventions utilized and health outcomes achieved.

Source MSNBC 08/08/2007
URL http://www.msnbc.msn.com/id/20184707/
Growth hormone can add 3 inches to short kids
Even with treatment, most children will be shorter than peers, study says
Reuters
Updated: 9:14 p.m. ET Aug. 8, 2007
NEW YORK - For short kids, treatment with growth hormone leads to height increases of up to 7.5 centimeters
(just under 3 inches), but the majority of these children will remain shorter than their peers.
Dr. Jackie R. Bryant of the University of Southampton, UK and colleagues came to this conclusion after studying
data from 10 trials involving 741 children with unexplained short stature.

Source PLoS Med 4(7): e235 doi:10.1371/journal.pmed.0040235
URL http://medicine.plosjournals.org/archive/1549-1676/4/7/pdf/10.1371_journal.pmed.0040235-L.pdf
South Africa's Experience of the Closure of the Cellulose Sulphate Microbicide Trial
Gita Ramjee*, Roshini Govinden, Neetha S. Morar, Anthony Mbewu
Funding: The authors received no specific funding for this article.
Competing Interests: The authors have declared that no competing interests exist.
Abbreviations: CS, cellulose sulphate; DOH, Department of Health; DSMC, data safety and monitoring committee;
HPRU, HIV Prevention Research Unit; MRC, Medical Research Council; PI, principal investigator
Gita Ramjee, Roshini Govinden, and Neetha S. Morar are with the HIV Prevention Research Unit, Medical
Research Council, Durban, KwaZulu-Natal, South Africa. Anthony Mbewu is President of the Medical Research
Council, Cape Town, Western Cape, South Africa.
* To whom correspondence should be addressed. E-mail: ramjeeg@mrc.ac.za
--------------------------------------------------------------------------------
In sub-Saharan Africa, almost 60% of HIV infections are among women [1], and the number of new HIV infections
in women worldwide continues to escalate. The high incidence of HIV in many African countries provides the
optimum environment for research on technologies that could prevent women from becoming infected, including
microbicides. In this article, we discuss the recent highly publicised closure of a trial of cellulose sulphate (CS),
which we conducted. We discuss the impact of the closure on the participants, the community at the trial site and
the public at large, the public health sector, national regulatory bodies, the media, and on other ongoing
microbicide trials. The local lessons that we learnt from the closure may provide guiding principles for researchers
and advocates in the HIV prevention field as a whole, who may face similar situations in the future.

Source Science 10 August 2007: Vol. 317. no. 5839, pp. 738 - 739
DOI: 10.1126/science.317.5839.738
URL http://www.sciencemag.org.gate2.inist.fr/cgi/reprint/317/5839/738.pdf
News of the Week
AIDS RESEARCH:
Feud Over AIDS Vaccine Trials Leads Prominent Italian Researchers to Court
Jon Cohen
Impassioned debates have swirled around several AIDS vaccines, with proponents aggressively pushing for
larger trials in humans and detractors contending that little evidence suggests that the given approach will
succeed. If no serious safety concerns exist, the issue typically comes down to money; peer-review committees,
blue-ribbon panels, or deep-pocketed pharmaceutical companies ultimately decide whether the trial receives the
many millions of dollars needed. But a dispute about the merits of an AIDS vaccine being developed by a leading
Italian researcher, Barbara Ensoli of the Istituto Superiore di Sanità (ISS) in Rome, has wound up in a different
venue: the courtroom. Ensoli is suing another prominent Italian investigator, immunologist Fernando Aiuti of the




Bénédicte de Boischevalier                      envoi du 10 août 2007                                               -5-
Ce dossier est destiné exclusivement à usage privé, suivant l'article L.122-5 du code de la propriété intellectuelle.
Quelque autre utilisation que ce soit est formellement interdite. Sont également interdits le prêt, la duplication et la
copie partielle ou totale de ce dossier Tous les droits de cette oeuvre sont réservés
University of Rome "La Sapienza," for what she contends is damage to her reputation. Aiuti, a former collaborator
of Ensoli's, has assailed what he sees as critical flaws in the early clinical trials of the vaccine.

Source BMJ 2007;335:304 (11 August), doi:10.1136/bmj.39297.500544.94
URL http://www.bmj.com.gate2.inist.fr/cgi/content/full/335/7614/304
Views & reviews
Personal views
Why do collaborative research?
Anisur Rahman, reader in rheumatology
Division of Medicine, University College London
anisur.rahman@ucl.ac.uk
Much of the most valuable medical research is done by large teams of people, often collaborating across several
centres. Examples include randomised controlled trials that prove the efficacy of new forms of treatment and
genetic studies that use clinical data from many hospitals to establish the linkage of genes to specific diseases.
Such collaborative efforts are undervalued by academic institutions, to the extent that it could be argued that
clinical academics who wish to thrive should avoid taking part in such collaborations—unless they are a lead
author. Without colleagues who are prepared to collaborate without gaining the kudos of leading, however, none
of these studies could be done.

Cellules souches, clonage, recherche sur l’embryon
Source Saint Louis Today 04/08/2007
URL
http://www.stltoday.com/stltoday/news/stories.nsf/editorialcommentary/story/AF3CCB9FE01A42928625732C007
FBBB8?OpenDocument
Danforth used disingenuous language to advance embryonic stem cell research agenda
08/04/2007
How is it possible to write an entire commentary about embryonic stem cell research without using the words
"embryo" or "embryonic"? By design. Former U.S. Sen. John Danforth did it in "Finding some common ground on
stem cells" (July 17).
A.F. Kertz | Glendale

Source Cell Stem Cell, Vol 1, 23-26, 07 June 2007
URL http://download.cellstemcell.com/pdfs/1934-5909/PIIS1934590907000094.pdf
Commentary
A Scientist's View of the Ethics of Human Embryonic Stem Cell Research
Anne McLaren1,
1 Wellcome Trust/Cancer Research UK Gurdon Institute, Tennis Court Road, Cambridge CB2 1QN, UK
Corresponding author
Anne McLaren
a.mclaren@gurdon.cam.ac.uk
Summary
Scientists are rarely immoral and seldom even amoral. The ethical principles that underlie much of their own work
are shared with scientists in other countries to a much greater degree than the cultural and religious differences
among those countries would lead one to expect. Like me, few will have had any formal training in bioethics; so
how might life scientists approach the varied ethical issues that arise in human embryo and stem cell research?

Source Cell Stem Cell, Vol 1, 27-34, 07 June 2007
URL http://download.cellstemcell.com/pdfs/1934-5909/PIIS1934590907000124.pdf
Commentary
Does Government Regulation Inhibit Embryonic Stem Cell Research and Can It Be Effective?
R.M.L. Winston1,
1 Institute of Reproductive and Developmental Biology, Division of Surgery, Oncology, Reproductive Biology and
Anaesthetics, Hammersmith Hospital Campus, Imperial College London, London W12 0HS, UK
Corresponding author
R.M.L. Winston
r.winston@imperial.ac.uk
Summary
The UK was one of the first countries to introduce legislation regulating embryo research, and the British
Parliament has taken a liberal view of the field. However, even in the UK, regulation of human embryonic stem
cell (ESC) research has had drawbacks, and the regulatory framework is somewhat inconsistent and imposes
considerable bureaucracy. There are around 33 countries that have broadly liberal legislation; each has a
different view of what is permissible. Only about eight of these countries have contributed significantly to
published research in the field. Paradoxically, in spite of tight federal restrictions, the USA remains the most
productive country in terms of the number and quality of peer review research publications. But even in our
increasingly global society, complex regulation will become progressively irrelevant and impossible to impose



Bénédicte de Boischevalier                      envoi du 10 août 2007                                               -6-
Ce dossier est destiné exclusivement à usage privé, suivant l'article L.122-5 du code de la propriété intellectuelle.
Quelque autre utilisation que ce soit est formellement interdite. Sont également interdits le prêt, la duplication et la
copie partielle ou totale de ce dossier Tous les droits de cette oeuvre sont réservés
effectively because attitudes will continue to vary widely in different countries and because of international travel
and trade. Consequently, there is a universal need for scientists to demonstrate their recognition of the ethical
and commercial conflicts that may arise in their research and engage in public debate and dialogue to ensure
responsible activity that benefits their research and reflects the values of society.

Europe

Source ESTOOLS and EuroStemCell 27 JULY 2007
URL http://www.eurostemcell.org/Documents/press_releases/27.07.07-JointStatement-estools-eurostemcell.pdf
Joint Statement
* The authors:
Giuseppe Testa is affiliated to the Laboratory of Stem Cell Epigenetics at the European Institute of Oncology in
Milano,
Italy, and is member of the independent Ethics Advisory Panel to the Board of Directors of ESTOOLS.
Lodovica Borghese, Julius Steinbeck and Oliver Brüstle are affiliated to the Institute of Reconstructive
Neurobiology at the University of Bonn / Life & Brain Center / Hertie Foundation, Germany which is an academic
partner in both consortia. Joint Statement
by the Directors of ESTOOLS and EuroStemCell
The impact of legislation in Europe on our ability to perform research using stem cells
…―ACTION IS NEEDED TO REMOVE POLITICAL AND LEGISLATIVE BARRIERS THAT HINDER COLLECTIVE
RESEARCH TO REALISE THE POTENTIAL OF STEM CELL RESEARCH FOR THE BENEFIT OF EUROPEAN
CITIZENS‖

Etats-Unis

Source Washington Post 29/07/2007
URL http://www.washingtonpost.com/wp-dyn/content/article/2007/07/28/AR2007072800993.html
Future of Stem Cell Tests May Hang on Defining Embryo Harm
By Rick Weiss
Washington Post Staff Writer
Sunday, July 29, 2007; A08
With the active encouragement of the Bush administration, U.S. scientists in the past year have developed
several methods for creating embryonic stem cells without having to destroy human embryos.
But some who now wish to test their alternatively derived cells have found themselves stymied by an unexpected
barrier: President Bush's stem cell policy.

Source The Los Angeles Times 01/08/2007
URL http://www.latimes.com/news/printedition/asection/la-na-stemcell1aug01,1,170552.story?ctrack=1&cset=true
From the Los Angeles Times
Stem cell dissent roils states
Even where voters have moved to support the embryonic research, opposition is fierce.
By Stephanie Simon
Times Staff Writer
August 1, 2007
KANSAS CITY, MO. — Nine months ago, Missouri voters became the first in the nation to pass a constitutional
amendment protecting embryonic stem cell research.
Ever since, opponents have been working feverishly to overturn it.
stephanie.simon@latimes.com

Source The New York Times 10/08/2007
URL http://www.nytimes.com/2007/08/10/us/10stemcell.html?_r=1&ref=health&oref=slogin
August 10, 2007
For Missouri, Stem Cell Amendment Changes Little
By MONICA DAVEY
ST. LOUIS — When Missouri voters approved a constitutional amendment last November protecting human
embryonic stem cell research, it was viewed as a key endorsement of the research even in states with deep
religious roots and strong antiabortion forces like this one.

Royaume Uni

Source Bionews 06/08/2007
URL http://www.bionews.org.uk/commentary.lasso?storyid=3530
The Human Tissue and Embryos Bill: a chance for further debate
Dr Mark Hamilton, Chair of the British Fertility Society and Consultant Gynaecologist, Aberdeen Maternity
Hospital' Today




Bénédicte de Boischevalier                      envoi du 10 août 2007                                               -7-
Ce dossier est destiné exclusivement à usage privé, suivant l'article L.122-5 du code de la propriété intellectuelle.
Quelque autre utilisation que ce soit est formellement interdite. Sont également interdits le prêt, la duplication et la
copie partielle ou totale de ce dossier Tous les droits de cette oeuvre sont réservés
Last week saw the publication of the UK parliamentary report of the Joint Committee on the Human Tissue and
Embryos (Draft) Bill. The government is now tasked to respond over the next two months in time for the Bill to be
included in the Queen's Speech in November.

Source PHGU 03/08/2007
URL http://www.phgfoundation.org/news/3567/
Parliamentary Joint Select Committee report on Human Tissue and Embryos (Draft) Bill
3 August 2007 | By Alison Hall | News story
 The UK Parliamentary Joint Select Committee published its report on the Human Tissue and Embryos (Draft) Bill
on 1 August 2007. The Committee has gathered an impressive array of evidence, engaged in novel methods of
public engagement (see previous news), and has produced a thoughtful and balanced report. It seems
appropriate that the opening chapters of the report deal with the central place of public opinion, and value of
ethical deliberation. The report notes that whilst a variety of witnesses claimed that their views reflected public
opinion ‗responses to public consultations often come from those with strong views which may not be
representative of those held by the general public‘ and the views expressed are by their nature self-selecting. As
a consequence, independent public policy research commissioned by Government is needed, as is a more active
approach by the Government and the regulator to improve and inform public understanding.
The Government is expected to publish a response to these proposals after the end of the Parliamentary recess
on 8 October.
http://www.publications.parliament.uk/pa/jt200607/jtselect/jtembryos/169/169.pdf

Source The Royal Society 23/07/2007
URL http://www.royalsoc.ac.uk/document.asp?tip=0&id=6842
Response to HFEA consultation on human-animal embryos in research
23 Jul 2007
Ref: 20/07
In July 2007, the Royal Society responded to scientific questions posed by the Human Fertilisation and
Embryology Authority (HFEA) in relation to the HFEA consultation on the ethical and social implications of
creating human-animal embryos in research..
http://www.royalsoc.ac.uk/displaypagedoc.asp?id=26264

Source Corethics 01/08/2007
URL http://www.corethics.org/index2.php?d=news&sb=1&item=8
Joint committee report on human tissues and embryos - faint praise but mostly huge disappointment
 (1 August, 2007)
If CORE had bet on the outcome of the Joint Committee Report (JCR), published today after two intense months
of evidence sessions and scrutiny, we would have got full marks.

Source Bionews 06/08/2007
URL http://www.bionews.org.uk/new.lasso?storyid=3536
 Parliamentary committee recommends sweeping changes to the Human Tissue and Embryos
(Draft) Bill
06 August 2007
By Danielle Hamm
A joint UK parliamentary committee, established to scrutinise the Human Tissue and Embryo (Draft) Bill, has
recommended that fundamental changes be made to the Bill before it commences its passage through
parliament. The draft Bill will replace the Human Fertilisation and Embryo Act 1990, which frames the law and
regulation around assisted reproduction and embryo research. The new Bill aims to update the law to take
account of fast moving technological advances in this area, and to reflect current attitudes to the ethical and social
issues surrounding this complex field.

Source Nature Reports Stem Cells Published online: 2 August 2007 | doi:10.1038/stemcells.2007.67
URL http://www.nature.com/stemcells/2007/0708/070802/full/stemcells.2007.67.html
Animal-human chimeras: Summary of UK Academy of Medical Sciences Report
Natalie DeWitt1
Highly varied experiments require case-by-base review.
Animal-human chimeras: Summary of UK Academy of Medical Sciences Report
Jean-Etienne Poirrier, Mel Curtis/Getty, Jessica Kolman
In September, the Human Fertilisation and Embryology Authority (HFEA) will make a policy decision on whether
research on animal-human chimeras should be allowed in the UK. The decision will be part of draft legislation to
update the 1990 law on assisted reproduction and embryology and to establish a regulatory authority for tissue
and embryos. As part of a period of public consultation, the UK Academy of Medical Sciences published a
thorough, well-reasoned report over relevant issues. The public comment period ended 20 July, and the HFEA
will make their policy decision in September.




Bénédicte de Boischevalier                      envoi du 10 août 2007                                               -8-
Ce dossier est destiné exclusivement à usage privé, suivant l'article L.122-5 du code de la propriété intellectuelle.
Quelque autre utilisation que ce soit est formellement interdite. Sont également interdits le prêt, la duplication et la
copie partielle ou totale de ce dossier Tous les droits de cette oeuvre sont réservés
Espagne

**Source Cell Stem Cell, Vol 1, 17-20, 07 June 2007
URL http://download.cellstemcell.com/pdfs/1934-5909/PIIS1934590907000033.pdf
Spanish Stem Cell Bank Interviews Examine the Interest of Couples in Donating Surplus
Human IVF Embryos for Stem Cell Research
Jose Luis Cortes,1, Guillermo Antiñolo,2 Luis Martínez,3 Fernando Cobo,1 Angela Barnie,1 Agustín Zapata,4 and
Pablo Menendez1,
1 Spanish Stem Cell Bank (Andalusian Central Node), Centro de Investigaciones Biomédicas, Parque
Tecnológico de las Ciencias de la Salud, Granada, Spain
2 Unidad Clínica de Genética y Reproducción, Hospital de la Mujer, Hospitales Universitarios Virgen del Rocio,
Sevilla, Spain
3 Unidad de Reproducción Asistida, Hospital Virgen de las Nieves, Granada, Spain
4 Spanish Stem Cell Bank, Instituto de Salud Carlos III, Madrid, Spain
Corresponding author
Pablo Menendez
pablo.menendez@juntadeandalucia.es
Corresponding author
Jose Luis Cortes
josel.cortes.sspa@juntadeandalucia.es
Main Text
Human embryonic stem cells (hES cells) were first derived in 1998 and hold great promise for opening up new
avenues in regenerative medicine through the generation of transplantable cells to be used in future cell
replacement therapies (Menendez et al., 2006, Reubinoff et al., 2000, Thomson et al., 1998). However, there is
extensive discussion about ethical aspects of the use of human embryos for stem cell research (Edwards, 2005, ,
2001, , 2002, McLaren, 2001). Part of this discussion relates to intense public debate about the ethics and
implications of in vitro fertilization (IVF) and its associated procedures (Edwards et al., 1997). In IVF treatment
cycles, the number of embryos generated usually exceeds the number that can be prudently transferred to the
future mother, and these surplus embryos can potentially be used for stem cell research. The 2003 SART-RAND
study estimated that at that time there were 400,000 stored embryos in 430 US IVF clinics (Hoffman et al., 2003,
Kaiser Network, 2007). In Spain, the estimate is that in 2003 there were 100,000 stored embryos in 203 Spanish
IVF clinics. In other countries, the specific legislative environment influences both the numbers of stored embryos
and their potential availability for donation for stem cell research (see, for example, Koeferl Puorger et al., 2006).
Despite being a very Catholic country, Spain currently represents a fairly permissive legal and ethical environment
for the use of excess embryos for hES cell research. Although IVF cycles must not be planned specifically for the
generation of human embryos to be used for stem cell research, cryopreserved embryos fewer than 14 days past
fertilization may be used for hES cell line derivation regardless of the length of time that they have been kept
frozen. Moreover, the Spanish government recently passed a bill to permit therapeutic cloning and cellular
reprogramming. The only requirement for hES cell line derivation and use is that the procedures must be linked to
a specific research project. Many countries, including Spain and the UK, have set up stem cell banks to provide
researchers with hES cell lines and facilitiate hES cell research. Although UK and Swedish legislation allow the
use of fresh embryos, most countries only permit donation of spare cryopreserved embryos for biomedical
research. Importantly, while embryos are becoming more accessible for physicians and embryologists who work
within IVF units, access to embryos for basic researchers in stem cell centers and academic institutions not
directly linked to an IVF clinic remains a major challenge.

Corée

Source Cell Stem Cell, Vol , Issue ,08/2007
URL http://download.cellstemcell.com/pdfs/1934-5909/PIIS1934590907000677.pdf
Recombination Signatures Distinguish Embryonic Stem Cells Derived by Parthenogenesis and
Somatic Cell Nuclear Transfer
Kitai Kim,1,2,4 Kitwa Ng,1,4 Peter J. Rugg-Gunn,5,9 Jae-Hung Shieh,6 Oktay Kirak,7 Rudolf Jaenisch,7 Teruhiko
Wakayama,8 Malcolm A. Moore,6 Roger A. Pedersen,5 and George Q. Daley1,2,3,4,
1 Division of Pediatric Hematology/Oncology, Children's Hospital Boston and Dana-Farber Cancer Institute,
Boston, MA 02115, USA
2 Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115,
USA
3 Division of Hematology, Brigham and Women's Hospital, Boston, MA 02115, USA
4 Harvard Stem Cell Institute, Boston, MA 02115, USA
5 Department of Surgery and Cambridge Institute for Medical Research, University of Cambridge, Cambridge,
CB2 2XY, UK
6 Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
7 Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
8 Center for Developmental Biology, RIKEN Kobe, Kobe 650-0047, Japan
Corresponding author




Bénédicte de Boischevalier                      envoi du 10 août 2007                                               -9-
Ce dossier est destiné exclusivement à usage privé, suivant l'article L.122-5 du code de la propriété intellectuelle.
Quelque autre utilisation que ce soit est formellement interdite. Sont également interdits le prêt, la duplication et la
copie partielle ou totale de ce dossier Tous les droits de cette oeuvre sont réservés
George Q. Daley
george.daley@childrens.harvard.edu
Summary
Parthenogenesis and somatic cell nuclear transfer (SCNT) are two methods for deriving embryonic stem (ES)
cells that are genetically matched to the oocyte donor or somatic cell donor, respectively. Using genome-wide
single nucleotide polymorphism (SNP) analysis, we demonstrate distinct signatures of genetic recombination that
distinguish parthenogenetic ES cells from those generated by SCNT. We applied SNP analysis to the human ES
cell line SCNT-hES-1, previously claimed to have been derived by SCNT, and present evidence that it represents
a human parthenogenetic ES cell line. Genome-wide SNP analysis represents a means to validate the genetic
provenance of an ES cell line.

Source LE MONDE | 03.08.07 | 12h57 • Mis à jour le 03.08.07 | 12h57
URL www.lemonde.fr
Clonage humain : l'affaire Hwang élucidée
L'une des plus belles et des plus tristes affaires de fraude scientifique dans le monde de la biologie cellulaire
vient, peut-être, de trouver son épilogue. Dans un article publié, jeudi 2 août, par la revue Cell Stem Cell, un
groupe de chercheurs américains, canadiens et japonais présente des données établissant, selon eux, en quoi le
Sud-Coréen Hwang Woo-suk a bien fraudé en affirmant être l'auteur du premier clonage humain. Ils montrent
aussi que leur confrère avait réalisé, semble-t-il à son insu, une première scientifique.
Jean-Yves Nau

Source The Scientist 02/08/2007
URL http://www.the-scientist.com/news/home/53460/
By Kelly Rae Chi
NEWS
Fabricated stem cell line origin revealed
Woo-suk Hwang et al.'s original embryonic stem cell line derived from parthenogenesis, new study confirms
Kelly Rae Chi
mail@the-scientist.com
Links within this article
I. Oransky, "All Hwang human cloning work fraudulent," The Scientist, Jan. 10, 2006.
http://www.the-scientist.com/news/display/22933/
Readers and Editors of The Scientist, "Cracking Cloning," The Scientist, June 2007.
http://www.the-scientist.com/2007/6/1/34/1/
C. Holding, "1st mouse by parthenogenesis?" The Scientist, April 21, 2004.
http://www.the-scientist.com/article/display/22124/
S. Pincock, "Seoul University to investigate Hwang cells," The Scientist, Dec. 12. 2005.
http://www.the-scientist.com/article/display/22858/
Seoul National University
http://www.useoul.edu
K. Kim, et al., "Recombination signatures distinguish embryonic stem cells derived by parthenogenesis and
somatic cell nuclear transfer," Cell Stem Cell, Sept. 2007.
http://www.vet.upenn.edu/profiles/kjmclaug/
Renee Reijo Pera
http://obgyn-nw.ucsf.edu/view_faculty.cfm?member=50
George Daley
http://www.childrenshospital.org/cfapps/research/data_admin/Site92/mainpageS92P0.html
Kevin Eggan
http://www.mcb.harvard.edu/Eggan/
E. S. Revazova, et al., "Patient-specific stem cell lines derived from human parthenogenetic blastocysts," Cloning
and Stem Cells, July 2007.
http://www.the-scientist.com/pubmed/17594198
Lifeline Cell Technology, LLC
http://www.lifelinecelltech.com/
J. Marchant, "Human eggs supply 'ethical' stem cells," Nature, June 29, 2006.
http://www.the-scientist.com/pubmed/16810217
S. Eckardt, "Hematopoietic reconstitution with androgenetic and gynogenetic stem cells," Genes & Devel, Feb.
15, 2007.
http://www.the-scientist.com/pubmed/17322401

Australie

Source News.com Australia 07/08/2007
URL http://www.news.com.au/story/0,23599,22202271-421,00.html#
NSW offers $500,000 for stem cell breakthrough
By Simon Benson
August 07, 2007 12:00am



Bénédicte de Boischevalier                      envoi du 10 août 2007                                             - 10 -
Ce dossier est destiné exclusivement à usage privé, suivant l'article L.122-5 du code de la propriété intellectuelle.
Quelque autre utilisation que ce soit est formellement interdite. Sont également interdits le prêt, la duplication et la
copie partielle ou totale de ce dossier Tous les droits de cette oeuvre sont réservés
SYDNEY could become the first city in the world to produce stem cells from cloned human embryos with a
$500,000 grant being offered by Premier Morris Iemma to the first scientist to do it.

Japon

Source Nature Reports Stem Cells Published online: 9 August 2007 | doi:10.1038/stemcells.2007.66
URL http://www.nature.com/stemcells/2007/0708/070809/full/stemcells.2007.66.html
Irrational Japanese regulations hinder human embryonic stem cell research
Norio Nakatsuji1
Although the principles regulating the research are sound, their implementation is onerous.
Norio Nakatsuji, Institute for Frontier Medical Sciences, Kyoto University

Génétique, OGM
Source Washington Post 06/08/2007
URL http://www.washingtonpost.com/wp-dyn/content/article/2007/08/05/AR2007080501636.html
Death Points to Risks in Research
One Woman's Experience in Gene Therapy Trial Highlights Weaknesses in the Patient Safety Net
By Rick Weiss
Washington Post Staff Writer
Staff researcher Madonna Lebling contributed to this report.

Source The Scientist 31/07/2007
URL http://www.the-scientist.com/news/home/53453/
By Chandra Shekhar
NEWS
Gene therapy trial on hold
Researchers say viral vector unlikely to be culprit in patient's death
Chandra Shekhar
mail@the-scientist.com
Links within this article:
A. Fischer and M. Cavazzana-Calvo, "Whither gene therapy?" The Scientist, February 1, 2006.
http://www.the-scientist.com/article/display/23064
J. Weitzman, "Gene therapy monkey business," The Scientist, August 21, 2002.
http://www.the-scientist.com/article/display/20615
Terence Flotte
http://www.mgm.ufl.edu/faculty/tflotte.htm
Theodore Friedmann
http://cancer.ucsd.edu/summaries/tfriedmann.asp
American Society of Gene Therapy
http://www.asgt.org/index.shtml
Mark Kay
http://kaylab.stanford.edu/Pages/marknew.html
Targeted Genetics
http://www.targen.com
J. F. Wilson, "Deconstructing Tumor Necrosis Factor," The Scientist, May 1, 2000.
http://www.the-scientist.com/article/display/11838
R. Weiss, "Suspended gene therapy test had drawn early questions," The Washington Post, July 28, 2007.
http://www.washingtonpost.com/wp-dyn/content/article/2007/07/27/AR2007072702242_pf.html
Recombinant DNA Activities Committee
http://www4.od.nih.gov/oba/rac/aboutrdagt.htm
P. Smaglik, "Investigators Ponder What Went Wrong," The Scientist, October 25, 1999.
http://www.the-scientist.com/article/display/18732
Targeted Genetics statement, July 26, 2007.
http://ir.targen.com/phoenix.zhtml?c=84981&p=irol-newsArticle&ID=1032343&highlight=
FDA statement, July 26, 2007.
http://www.fda.gov/bbs/topics/NEWS/2007/NEW01672.html
Introgen Therapeutics
http://www.introgen.com
Celladon Corporation
http://www.celladon.net

Source Science 3 August 2007: Vol. 317. no. 5838, p. 580
DOI: 10.1126/science.317.5838.580
URL http://www.sciencemag.org.gate2.inist.fr/cgi/reprint/317/5838/580.pdf
News of the Week



Bénédicte de Boischevalier                      envoi du 10 août 2007                                             - 11 -
Ce dossier est destiné exclusivement à usage privé, suivant l'article L.122-5 du code de la propriété intellectuelle.
Quelque autre utilisation que ce soit est formellement interdite. Sont également interdits le prêt, la duplication et la
copie partielle ou totale de ce dossier Tous les droits de cette oeuvre sont réservés
CLINICAL RESEARCH:
Death Prompts a Review of Gene Therapy Vector
Jocelyn Kaiser
The death last week of a patient receiving experimental gene therapy for arthritis has triggered a federal review of
all trials using the same vector. Few details have been made public; if it turns out that the therapy is to blame, it
would be another blow to the field's image. Within 8 years, one patient has died as a result of gene therapy and
three have acquired leukemia. This would be the first fatality in a trial not studying a life-threatening disease.
The trial's sponsor, Targeted Genetics Corp. in Seattle, Washington, emphasizes that the company doesn't yet
know what caused the patient's death. But it would be a surprise if it were the viral vector, says Chief Scientific
Officer Barrie Carter, given that the vector has proved safe in hundreds of patients. He and others are watching
nervously for the results of an investigation by the company and the U.S. Food and Drug Administration (FDA).
Carter believes it could take weeks. "I just hope it doesn't put a mark on the entire field," says molecular
orthopedist Christopher Evans of Harvard Medical School in Boston, who is also planning a test of gene therapy
to treat arthritis.

Source US Pharma 08/08/2007
URL http://us-pharmatechnologist.com/news/ng.asp?n=78886-targeted-genetics-gene-therapy-clinical-trials
Breaking News on Pharmaceutical Technology - North America
Speculation on gene therapy trial death 'premature'
By Emilie Reymond
 08/08/2007- Targeted Genetics said it was "premature as well as irresponsible" to draw any conclusions on what
caused the death of a patient who participated in a clinical trial testing the safety of the firm's new gene therapy.
The biotech company was reacting to an article published in the Washington Post on Monday which alleged that
the way the recruitment of the patient, who died on 24 July, was conducted was in serious breach of clinical trial
regulation standards.


Source Science 3 August 2007: Vol. 317. no. 5838, p. 585
DOI: 10.1126/science.317.5838.585a
URL http://www.sciencemag.org.gate2.inist.fr/cgi/reprint/317/5838/585a.pdf
News of the Week
FRANCE:
Cancer Test Dispute Pits Researcher Against a Firm She Helped Create
Martin Enserink
 Size matters. An ISET filter has pores (2) small enough to let blood cells (3) pass, while tumor cells (1) are
captured.
PARIS--When Patrizia Paterlini first reported a cheap and rapid technology to detect tumor cells in blood 7 years
ago, she hoped it might make it to the market. Today, she's fighting to prevent precisely that. Paterlini, an
oncologist at the French biomedical research agency INSERM, is trying to stop Metagenex, a company in which
her family owns a 44% share, from selling testing equipment based on her technology, which she says has not
been sufficiently validated. Offering the test to doctors now, she says, is "unscientific." Government inspectors
and two ethics panels are investigating the issue, which has also embroiled Paterlini's husband, INSERM director
Christian Bréchot.

Source Science 3 August 2007: Vol. 317. no. 5838, pp. 600 - 602
DOI: 10.1126/science.1147699
URL http://www.sciencemag.org.gate2.inist.fr/cgi/reprint/317/5838/600.pdf
Policy Forum
ETHICS:
Identifiability in Genomic Research
William W. Lowrance1 and Francis S. Collins2
Genomic research can now readily generate data that cover significant portions of the human genome at levels of
detail unique to individuals. Data can now be categorized with respect to disease-related genes and linked to
clinical, family, and social data. Identifiability, the potential for such data to be associated with specific individuals,
is therefore a pivotal concern. Research, health care, police, military, and other DNA and genotype reference
collections are growing. Members of the public and its leaders worry about risks of erroneous or malicious identity
disclosure and consequent embarrassment; legal or financial ramifications; stigmatization; and/or discrimination
for insurance, employment, promotion, or loans.
1W. W. Lowrance is a consultant in health research policy and ethics, 72 rue de St. Jean, CH-1201 Geneva,
Switzerland; e-mail: lowrance@iprolink.ch .
2F. S. Collins is director, U.S. National Human Genome Research Institute, Bethesda, MD 20892-2152 USA; e-
mail: francisc@mail.nih.gov

Source Nature 448, 631 (9 August 2007) | doi:10.1038/448631a; Published online 8 August 2007
URL http://www.nature.com.gate2.inist.fr/nature/journal/v448/n7154/pdf/448631a.pdf
US genetics bill blocked again
Meredith Wadman



Bénédicte de Boischevalier                       envoi du 10 août 2007                                                - 12 -
Ce dossier est destiné exclusivement à usage privé, suivant l'article L.122-5 du code de la propriété intellectuelle.
Quelque autre utilisation que ce soit est formellement interdite. Sont également interdits le prêt, la duplication et la
copie partielle ou totale de ce dossier Tous les droits de cette oeuvre sont réservés
Abstract One-man lobby halts antidiscrimination law.
Related links
RELATED STORIES
     Discriminating on genes
     News in brief
     News in brief
RELATED LINKS
NPG journals on genetics
EXTERNAL LINKS
     Genetic Information Nondiscrimination Act as passed by the US House
     Senator Tom Coburn
     Genetics and Public Policy Center

Source Seattle Times 06/08/2007
URL http://seattletimes.nwsource.com/html/businesstechnology/2003823272_gene06.html
Targeted Genetics drug puts clinical trials in spotlight
By Rick Weiss
The Washington Post
WASHINGTON — Robb Mohr sat by his wife's hospital bed two weeks ago, trying to take it all in. His wife, Jolee
Mohr, was breathing with the help of a ventilator in a Chicago intensive-care unit — her body bloated from internal
bleeding, her liver failing — and no one could figure out what was wrong with her.

Pharmacogénétique
Source Technology Review 02/08/2007
URL http://www.technologyreview.com/printer_friendly_article.aspx?id=19135
Thursday, August 02, 2007
More-Accurate Cancer Treatment
A computer model can predict which drugs a cancer patient will respond to best.
By Katherine Bourzac

Source Nature Reviews Drug Discovery 6, 587 (August 2007) | doi:10.1038/nrd2385
URL http://www.nature.com.gate2.inist.fr/nrd/journal/v6/n8/pdf/nrd2385.pdf
Getting personal
Abstract The possibility of more widespread application of 'personalized medicine', in which therapy is tailored to
factors such as an individual's genetic make-up, has been on the horizon for years, but so far, translation of this
concept to clinical practice has been limited. What might it take to change this situation?

Source Scientific American 15/07/2007
URL http://www.sciam.com/article.cfm?chanID=sa006&articleID=B0FEC94D-E7F2-99DF-
3CD8F25918B63A39&pageNumber=1&catID=2&colId=1
July 15, 2007
Race in a Bottle
Drugmakers are eager to develop medicines targeted at ethnic groups, but so far they have made poor choices
based on unsound science
By Jonathan Kahn
For other related articles by Jonathan Kahn, go to http://ssrn.com/author=180388

Source Venture Beat 08/08/2007
URL http://venturebeat.com/index.php?p=22186&print=1
Personalized medicine takes a (tiny) step forward
Posted By David Hamilton On August 8, 2007 @ 1:28 pm In lifesciences | No Comments
(UPDATED: See below.)
[1] ―personalized medicine‖ revolution is coming to pass.
On Monday, the field took a baby step forward when the FDA approved Selzentry, a new AIDS drug from [2]
Pfizer. Selzentry is unique in a number of ways — for instance, it‘s the first drug that tries to ―lock down‖ T-cells to
prevent HIV (that‘s the culprit, above and to the left) from entering and infecting them. Fuzeon, a less-than-
successful drug from [3] Roche and [4] Trimeris, does something similar, although it works to gum up HIV‘s
―landing gear,‖ not the T-cell‘s docking port.
URLs in this post:
[1] ―personalized medicine‖:
http://www.pwc.com/extweb/pwcpublications.nsf/docid/3B11C597C386E52385256FB1006F945B
[2] Pfizer: http://www.pfizer.com
[3] Roche: http://www.roche.com
[4] Trimeris: http://www.trimeris.com



Bénédicte de Boischevalier                      envoi du 10 août 2007                                              - 13 -
Ce dossier est destiné exclusivement à usage privé, suivant l'article L.122-5 du code de la propriété intellectuelle.
Quelque autre utilisation que ce soit est formellement interdite. Sont également interdits le prêt, la duplication et la
copie partielle ou totale de ce dossier Tous les droits de cette oeuvre sont réservés
[5] Monogram Biosciences: http://www.monogrambio.com
[6] this Monogram press release: http://ir.monogrambio.com/releasedetail.cfm?ReleaseID=258543
[7] Herceptin: http://en.wikipedia.org/wiki/Trastuzumab
[8] Arca Discovery: http://www.arcadiscovery.com/
[9] here: http://venturebeat.com/2007/06/12/arca-discovery-raises-18m-for-cardiovascular-drug/
[10] me-too drugs: http://www.washingtonpost.com/ac2/wp-dyn/A43257-2003Nov14?language=printer
[11] half-dozen statins: http://heartdisease.about.com/cs/cholesterol/a/statins.htm
[12] This: http://www.marginalrevolution.com/marginalrevolution/2004/12/metoo_drugs.html
[13] argument: http://www.economist.com/blogs/freeexchange/2007/04/me_too_me_too.cfm
[14] this Reuters story:
http://www.redorbit.com/news/health/247326/personalized_medicines_overhyped_report_says/index.html
[15] here: http://lifesciences.venturebeat.com

Biobanque
Source MediLexicon 08/08/2007
URL http://www.medilexicon.com/medicalnews.php?newsid=79075
Umbilical Cord Blood Bill Passed Into Law
08 Aug 2007
New York Assemblyman Joseph R. Lentol announces the signing of the Umbilical Cord Blood Bill into law by
Governor Eliot Spitzer, Chapter 427 of 2007.
Anyone interested in learning more about Umbilical Cord Blood Stem Cells should go to
http://www.cordbloodawareness.org .
Assemblyman Joseph R. Lentol
http://www.cordbloodawareness.org

Neurosciences
Source LE MONDE | 07.08.07 | 12h41 • Mis à jour le 07.08.07 | 16h57
URL www.lemonde.fr
La machine qui détecte la personnalité
Assis sur une chaise, on vous pose deux électrodes sur le front et on vous demande de mettre vos pieds nus et
vos mains sur des plaques en acier. Ces six "points de contact" sont reliés à un boîtier lui-même branché sur un
ordinateur. Ainsi installé, les seules consignes sont de donner son âge et de ne pas bouger pendant trente
secondes.
Renseignements : www.quanticpotential.com
Sandrine Blanchard
Article paru dans l'édition du 08.08.07

Médicaments, industrie pharmaceutique

Pays en développement
Source The Lancet Volume 370, Issue 9585, 4 August 2007-10 August 2007, Page 362
URL http://www.sciencedirect.com.gate2.inist.fr/science?_ob=ArticleURL&_udi=B6T1B-4PB8KWD-
2&_user=2579232&_coverDate=08%2F10%2F2007&_rdoc=2&_fmt=full&_orig=browse&_srch=doc-
info(%23toc%234886%232007%23996290414%23664838%23FLA%23display%23Volume)&_cdi=4886&_sort=d
&_docanchor=&_ct=37&_acct=C000020819&_version=1&_urlVersion=0&_userid=2579232&md5=6426ad70e136
04308938553771e1063d
Europe's clinical trials partnership programme in peril
Available online 2 August 2007.
On July 17, the findings of an independent expert group on the troubled European and Developing Countries
Clinical Trials Partnership (EDCTP) programme were released. The review was commissioned by the European
Commissioner for Research Janez Potočnik following a very critical European Court of Auditors report in 2005
and ahead of a possible new funding round.

Source Centre de Recherche Cultures, Santé, Sociétés
URL http://www.mmsh.univ-aix.fr/crecss/atelierEthiqueParis.htm
ATELIER INTERNATIONAL: "L'ETHIQUE DE LA RECHERCHE EN SANTE DANS LES PAYS DU
SUD. PARIS 2007"
DOCUMENTS DE TRAVAIL
Le CReCSS a co-organisé ce colloque qui s'est tenu à Paris les 2 et 3 avril 2007. L'Atelier a été organisé par le
Dr Marie Ahouanto, à l'initiative du GISPE (Groupe d'Intervention en Santé Publique et Epidémiologie), avec la
participation du Ministère des Affaires Etrangères, de l'Agence Nationale de Recherches sur le Sida et les




Bénédicte de Boischevalier                      envoi du 10 août 2007                                             - 14 -
Ce dossier est destiné exclusivement à usage privé, suivant l'article L.122-5 du code de la propriété intellectuelle.
Quelque autre utilisation que ce soit est formellement interdite. Sont également interdits le prêt, la duplication et la
copie partielle ou totale de ce dossier Tous les droits de cette oeuvre sont réservés
hépatites virales, et sous le parrainage de la Société de Pathologie Exotique et le haut patronage de la
Commission Française pour l‘UNESCO.
Les Photos, le Thème de l'Atelier (français seulement), le Programme, la Liste des participants sont
téléchargeables dans la marge.
La liste des communications est présentée ci-dessous, avec, dans certains cas, les diapositives des orateurs qui
peuvent être consultées ou téléchargées.
Introduction à l‘atelier
Didier Sicard. L'éthique à géométrie variable.
Avancées conceptuelles et questions pratiques autour de la charte éthique de l‘ANRS
Christian Byk. Les règles applicables aux recherches menées sur le sida dans les pays en développement.
Brigitte Bazin. La Charte d‘éthique de l‘ANRS sur la recherche dans les pays en développement : démarche,
contenu, implications. [pdf com Ethique\Bazin.pdf]
Ingrid Callies. L'évolution de la charte d'éthique de la recherche de l'ANRS. [pdf com Ethique\Callies.pdf]
Xavier Anglaret. Pour la disparition d‘une charte éthique de la recherche « dans les pays en développement ».
Rose Dossou
Jean-Marie Talom.
Quel consentement éclairé ?
Michèle Guillaume-Hofnung. Ethique, médiation et consentement éclairé.
Marie de Cenival. « Consentir à y entrer ? Liberté d‘en sortir !» Réflexion pour un changement de paradigme.
[pdf com Ethique\deCenival.pdf]
Problématique des essais de prévention (vaccins, microbicides)
Jean-Philippe Chippaux. Quelle éthique pour les essais de prévention ? [pdf com Ethique\Auvert.pdf]
Charles Kaduwa. Discussion points on the problems associated with prevention trials.
Bertran Auvert. Réflexions autour de l‘essai circoncision. [ p[df com Ethique\Ukpong.pdf]
Jean-Marie Talom. Les essais de prévention : quels enjeux ?
Morenike Upkong. Problems of HIV prevention trials. p[df com Ethique\Ukpong.pdf]
Henriette Meillo (SWAA, Cameroun) Nécessité des essais de prévention: mais avec quelles normes?
Chan Inn.
Paisan Suwannawong. Problems of Prevention Trials: Perspective on the Thai Tenofovir PREP among IDU
Study. [pdf com Ethique\Suwannawong.pdf]
Didier Lestrade.
Chercheurs du Sud et du Nord : quel partenariat ?
Abdelkader Herari. Les médicaments essentiels, le partenariat Nord-Sud, et l‘éthique[pdf com
Ethique\Herari.pdf]Fred Eboko.
L'éthique dans la recherche en sciences sociales, humaines et économiques
 Alice Desclaux. Les normes éthiques de la recherche médicale sont-elles inapplicables en sciences sociales?
[pdf com Ethique\Desclaux.pdf]
Les comités d'éthique dans les pays à ressources limitées
Charles Becker. Comment tirer profit de l'expérience acquise et des ressources existantes ?
Bernard Taverne. Observations issues du comité d'éthique du Sénégal (2003-2006).
Achille Massougbodji. NEBRA : une initiative nord-sud de renforcement de l‘éthique de la recherche en Afrique.
[pdf com Ethique\Massoubodgi.pdf]
Bernard Liautaud. Deux comités pour une recherche ?
Solomon Kapere. Comités d‘éthique : quel rôle dans l‘essai DART ?
Quels standards de soins ?
Christine Toneatti. Quels principes retenir pour mettre en place une démarche qualité en recherche dans un pays
à ressources limitées? pdf com Ethique\Toneatti.pdf]
Philippe Msellati. Prise en charge accompagnant la recherche : quels standards de soins [pdf com
Ethique\Msellati.pdf]
Donald de Korte. Expérience d'études cliniques en Afrique sub-saharienne, point de vue de l'industrie
pharmaceutique. [[pdf com Ethique\deKorte.pdf]
Recherche clinique et médecine traditionnelle
Pascal Niamba. Ethique et médecine traditionnelle: expérience dans la prise en charge des personnes infectées
par le VIH au Burkina Faso. [pdf com Ethique\Niamba.pdf]
Bernard Taverne. Recherche clinique et médecine traditionnelle – télescopage épistémologique et reproduction
de l‘ordre social. [[pdf com Ethique\Taverne.pdf]
Regard et place des communautés dans la recherche
Morenike Upkong. Importance and place of the community in Research. pdf com Ethique\Ukpong2.pdf]
Paisan Suwannawong. Perception and Role of Communities in Research.
Berthé Abdramane. Regard et place de la communauté bobolaise dans les essais cliniques (Burkina Faso).
Chan Inn.
Charles Kaduwa. View and place of communities in trials. [pdf com Ethique\Kaduwa.pdf]
Solomon Kapere. Essai DART : Quels enseignements pour la communauté ?
Enjeux politiques des recherches menées dans les pays à ressources limitées
Marc Dixneuf. Enjeux politiques des recherches menées dans les pays du Sud.



Bénédicte de Boischevalier                      envoi du 10 août 2007                                             - 15 -
Ce dossier est destiné exclusivement à usage privé, suivant l'article L.122-5 du code de la propriété intellectuelle.
Quelque autre utilisation que ce soit est formellement interdite. Sont également interdits le prêt, la duplication et la
copie partielle ou totale de ce dossier Tous les droits de cette oeuvre sont réservés
Christian Laurent. Essai Triomune ANRS 1274 : du questionnement sur sa pertinence à son impact en santé
publique. [pdf com Ethique\Laurent.pdf]
Conclusions

Nanotechnologies
Source Unesco 2007
URL http://publishing.unesco.org/details.aspx?&Code_Livre=4539&change=F
Nanotechnologies, Ethics and Politics
Edited by Henk A. M. J. ten Have.
Ethics Series
Livre, 244 pages, figures, tables, index, annex, bibliography
Format: 24 x 15,5 cm
2007, 978-92-3-104051-1
UNESCO Publishing
L'UNESCO a invité des experts en nanotechnologies à faire un état des lieux de leur discipline, à examiner les
controverses entourant sa définition et à explorer des sujets éthiques et politiques liés. Ce livre est disponible
uniquement en anglais.

Expérimentation animale
Source Cordis 06/08/2007
URL http://cordis.europa.eu/fetch?CALLER=FR_NEWS&ACTION=D&&SESSION=&&&RCN=28164
Un groupe d'éthique lance une consultation sur le clonage animal à des fins
d'approvisionnement alimentaire
[Date: 2007-08-06]
Le Groupe européen sur l'éthique des sciences et des nouvelles technologies (European Group on Ethics - EGE)
a lancé une consultation publique sur les aspects éthiques du clonage animal à des fins d'approvisionnement
alimentaire.
Pour de plus amples informations, consulter:
http://ec.europa.eu/european_group_ethics/public_consultation_form.htm

Source Journal officiel des Communautés européennes 30/06/2007
URL http://eur-lex.europa.eu/LexUriServ/site/en/oj/2007/l_197/l_19720070730en00010089.pdf
RECOMMENDATIONS
COMMISSION
COMMISSION RECOMMENDATION of 18 June 2007 on guidelines for the accommodation and
care of animals used for experimental and other scientific
purposes
(notified under document number C(2007) 2525)
(Text with EEA relevance)
(2007/526/EC)

Intégrité scientifique
Source The Scientist 07/08/2007
URL http://www.the-scientist.com/news/home/53469/
By Alla Katsnelson
NEWS
Former UPenn postdoc faked images
Nineteen manipulated images prompted two retractions, according to ORI
Alla Katsnelson
mail@the-scientist.com
Links within this article:
The Office of Research Integrity
http://ori.dhhs.gov/
Morris Birnbaum
http://www.med.upenn.edu/crrwh/faculty/Birnbaum/Birnbaum.html
K. Roovers and R.K. Assoian, "Effects of rho kinase and actin stress fibers on sustained extracellular signal-
regulated kinase activity and activation of G(1) phase cyclin-dependent kinases," Mol. Cell Biol., June, 2003.
http://www.the-scientist.com/pubmed/12773570
K. Roovers et. al., "Nuclear translocation of LIM kinase mediates Rho-Rho kinase regulation of cyclin D1
expression," Dev. Cell, August, 2003.
http://www.the-scientist.com/pubmed/12919678




Bénédicte de Boischevalier                      envoi du 10 août 2007                                             - 16 -
Ce dossier est destiné exclusivement à usage privé, suivant l'article L.122-5 du code de la propriété intellectuelle.
Quelque autre utilisation que ce soit est formellement interdite. Sont également interdits le prêt, la duplication et la
copie partielle ou totale de ce dossier Tous les droits de cette oeuvre sont réservés
C.F. Welsh et. al., "Timing of cyclin D1 expression within G1 phase is controlled by Rho," Nat. Call Biol.,
November, 2001.
http://www.the-scientist.com/pubmed/11715015
Anthony Muslin
http://dbbs.wustl.edu/dbbs/website.nsf
D. Secko, "Mending broken hearts," The Scientist, August 11, 2003.
http://www.the-scientist.com/article/display/21524
B. DeBosch et al., "Akt1 is required for physiological cardiac growth," Circulation, May 2, 2006.
http://www.the-scientist.com/pubmed/16636172
Glen Gaulton
http://www.med.upenn.edu/camb/faculty/mv/gaulton.html
Richard Assoian
http://www.med.upenn.edu/camb/faculty/cbp/assoian.html
Martin Schwartz
http://www.med.upenn.edu/camb/faculty/cbp/assoian.html
Thomas Stossel
http://www.researchmatters.harvard.edu/people.php?people_id=749
Y. Ohta et al., "FilGAP, a Rho- and ROCK-regulated GAP for Rac binds filamin A to control actin remodeling,"
Nat. Cell Biol, August, 2006.
http://www.the-scientist.com/pubmed/16862148

Ethique
Source Le Figaro 02/08/2007
URL
http://www.lefigaro.fr/debats/20070802.FIG000000014_lutter_contre_la_maladie_d_alzheimer_c_est_une_urgenc
e_democratique.html
Lutter contre la maladie d'Alzheimer, c'est une urgence démocratique.
 Publié le 02 août 2007Actualisé le 02 août 2007 : 09h44
Par Emmanuel Hirsch, directeur de l'Espace éthique AP-HP et du département de recherche en éthique,
université Paris-Sud XI.
Considérée au plan national comme une priorité politique, la maladie d'Alzheimer sollicite désormais une
mobilisation sociale qui ne saurait se limiter aux dispositifs institutionnels de suivi et de soutien. Elle en appelle à
une autre culture de la solidarité, dans un contexte de vulnérabilité qui affecte la personne malade et ses proches
trop souvent stigmatisés par les connotations liées aux représentations de la démence. Il convient de modifier
nos attitudes encore influencées par les mentalités de l'exclusion, donc de comprendre les enjeux d'une
responsabilité assumée ensemble au sein de la cité.

Source Times of India 08/08/2007
URL
http://timesofindia.indiatimes.com/World/Rest_of_World/S_Koreas_code_of_ethics_for_robots/articleshow/22635
94.cms
S Korea's code of ethics for robots
8 Aug 2007, 0004 hrs IST,AFP
SEOUL: South Korea, at the forefront of the drive to develop robots which can do anything from guarding the
border to caring for the elderly, is now drawing up a code of ethics for them.

Traitement compassionnel
Source Wasghington Post 07/08/2007
URL http://www.washingtonpost.com/wp-dyn/content/article/2007/08/07/AR2007080701161.html
Court Rules Out Terminally Ill for Tests
By MATT APUZZO
The Associated Press
Tuesday, August 7, 2007; 8:19 PM
WASHINGTON -- Terminally ill patients do not have a constitutional right to be treated with experimental drugs,
even if they likely will be dead before the medicine is approved, a federal appeals court said Tuesday.
The ruling by the U.S. Court of Appeals for the District of Columbia Circuit overturned last year's decision by a
smaller panel of the same court, which held that terminally ill patients may not be denied access to potentially

Source The New York Times 08/08/2007
URL http://www.nytimes.com/2007/08/08/health/08cancer.html?ref=health
Court Rejects the Right to Use Drugs Being Tested
By ANDREW POLLACK
A federal appeals court ruled yesterday that patients with terminal illnesses do not have a constitutional right to
use medicines that have not yet won regulatory approval.



Bénédicte de Boischevalier                      envoi du 10 août 2007                                             - 17 -
Ce dossier est destiné exclusivement à usage privé, suivant l'article L.122-5 du code de la propriété intellectuelle.
Quelque autre utilisation que ce soit est formellement interdite. Sont également interdits le prêt, la duplication et la
copie partielle ou totale de ce dossier Tous les droits de cette oeuvre sont réservés


Publication, open access
Source NIH 08/2007
URL http://www.nih.gov/about/director/newsletter/Summer2007.htm
Reviewing Peer Review: NIH needs your help!
Please take a few minutes to respond to the NIH Request for Information on Peer Review at:
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-07-074.html
We all rely on the NIH peer review system to ensure that we support the best biomedical and behavioral research
in the world. Today, we can all agree that the system faces challenges. These challenges include, among others,
a rising number of applications, rapid changes in science, and increasingly competitive funding levels, all of which
require many investigators to apply multiple times to obtain funding.
I invite you to share any comments you have with me, directly, at zerhounidirect@nih.gov .
Elias A. Zerhouni, M.D., Director
National Institutes of Health

Source The Scientist 06/08/2007
URL http://www.the-scientist.com/news/home/53446/
By The Scientist staff
NEWS
Special feature: How should scientists sell science?
Tell us whether you think researchers should change the way they communicate hot-button issues to the public
Links within this article:
M.C. Nisbet and C. Mooney. Framing science. Science, April 6, 2007.
http://www.the-scientist.com/pubmed/17412941
M.C. Nisbet and C. Mooney. Thanks for the facts, now sell them. Washington Post April 15, 2007.
http://www.washingtonpost.com/wp-dyn/content/article/2007/04/13/AR2007041302064_pf.html
One-stop shopping for the framing science debate.
Science & Politics April 20, 2007.
http://sciencepolitics.blogspot.com/2007_04_01_archive.html

Source Science 3 August 2007: Vol. 317. no. 5838, p. 582
DOI: 10.1126/science.317.5838.582
URL http://www.sciencemag.org.gate2.inist.fr/cgi/reprint/317/5838/582.pdf
News of the Week
SCIENTIFIC PUBLISHING:
U.S. Output Flattens, and NSF Wonders Why
Jeffrey Mervis
A new study by the National Science Foundation (NSF) showing that the overall number of publications by U.S.
scientists has remained flat for more than a decade calls to mind the opening words of a classic 1960s folk rock
anthem: "There's something happening here; what it is ain't exactly clear."

Source Journal of Vascular Surgery Volume 46, Issue 2, August 2007, Pages 391-393
URL http://www.sciencedirect.com.gate2.inist.fr/science?_ob=ArticleURL&_udi=B6WMJ-4P94VN2-
14&_user=2579232&_coverDate=08%2F31%2F2007&_alid=607093006&_rdoc=13&_fmt=full&_orig=search&_cdi
=6936&_sort=d&_st=4&_docanchor=&_ct=208&_acct=C000020819&_version=1&_urlVersion=0&_userid=257923
2&md5=e8680faf8953023ec1a03094956de29d
Ethics of guidelines for reviewers of medical manuscripts
David Minion MDa, Ehab Sorial MDa and Eric Endean MD, a,
aUniversity of Kentucky College of Medicine, Lexington, Ky.
Received 25 January 2007; accepted 17 May 2007. Available online 28 July 2007.
Referred to by: Reviewer responsibility
Journal of Vascular Surgery, Volume 46, Issue 2, August 2007, Page 181
Jack L. Cronenwett, James M. Seeger, Louis M. Messina and Bruce A. Perler
An ounce of prevention is worth a pound of cure.
Benjamin Franklin
Case 1
The editors of a vascular surgery journal requested that a submitted manuscript be reviewed by an ad hoc peer
reviewer. The editors chose the reviewer because of her known interest and expertise in the specific topic. The
surgeon viewed the abstract and agreed to provide the journal with a review. When she received the full
manuscript, the reviewer recognized that the submitted manuscript was very similar to a clinical project that she
was currently working on. She had been considering submitting the results of her own similar project to the same
journal.
Case 2
A manuscript describing a novel modification of a surgical technique was submitted to a vascular surgery journal
and underwent peer review. One of the reviewers returned a critique that went into extensive detail describing



Bénédicte de Boischevalier                      envoi du 10 août 2007                                             - 18 -
Ce dossier est destiné exclusivement à usage privé, suivant l'article L.122-5 du code de la propriété intellectuelle.
Quelque autre utilisation que ce soit est formellement interdite. Sont également interdits le prêt, la duplication et la
copie partielle ou totale de ce dossier Tous les droits de cette oeuvre sont réservés
how the reviewer also used this modification, although with slightly different variations than that described by the
author. The manuscript was accepted for publication. Two months after it was published, a second manuscript
was published in the same journal by another group describing their modification of the same surgical technique.
The wording of the second manuscript was remarkably similar to the critique provided for the original work,
suggesting that it was submitted by the individual who provided the peer review of the first manuscript. The
original work was not acknowledged or referenced in the second publication.

Source Biomaterials Article in Press, Corrected Proof 07/2007
URL http://www.sciencedirect.com.gate2.inist.fr/science?_ob=ArticleURL&_udi=B6TWB-4P83D5M-
4&_user=2579232&_coverDate=07%2F23%2F2007&_alid=607093006&_rdoc=24&_fmt=full&_orig=search&_cdi=
5558&_sort=d&_st=4&_docanchor=&_ct=208&_acct=C000020819&_version=1&_urlVersion=0&_userid=2579232
&md5=85c4339f7737814ca93611eda8ef3887
Peer review as professional responsibility: A quality control system only as good as the
participants
David W. Graingera, b, ,
aDepartment of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, Room 301, 30 South 2000
East, University of Utah, Salt Lake City, UT 84112-5820, USA
bDepartment of Bioengineering, University of Utah, Salt Lake City, UT 84112-5820, USA
Received 17 June 2007; accepted 1 July 2007. Available online 23 July 2007.
Abstract
The peer-review process remains a central part of the value and validity of scientific and technical publishing and
proposal assessment. The peer review mechanism has many delicate components that should function most
professionally and effectively for best results. An important central tenet is that all who seek to publish should
freely avail themselves to review a commensurate load, considering many elements of professional conduct,
ethics and responsibility in this process. The review itself should provide timely, unbiased, quality feedback to
improve contributions to the system reviewers are serving. An additional component involves follow-on policing of
published literature to assert its validity through consensus and validation. This short essay examines our
collective duties as contributors, reviewers, and readers to the integrity and safekeeping of this essential quality
control process.
Keywords: Peer review; Scientific publishing; Professional conduct; Quality control; Responsibility

Source The Scientist 09/08/2007
URL http://www.the-scientist.com/news/home/53450/
By Andrea Gawrylewski
NEWS
Yale dumps BioMedCentral
The research institution decides not to renew membership to the open access publishing company
Andrea Gawrylewski
mail@the-scientist.com
Links within this article:
Yale library statement
href=' http://www2.library.yale.edu/movabletype/scilib/archive/2007/08/library_drops_b_1.html
Association of Research Libraries
href=' http://www2.library.yale.edu/movabletype/scilib/archive/2007/08/library_drops_b_1.html
Peter Suber
http://www.earlham.edu/~peters/hometoc.htm
Open Access Project
http://www.publicknowledge.org/about/what/projects/open-access.html
T. Agres. "'Open Access' opens wider," The Scientist, July 5, 2007.
http://www.the-scientist.com/news/display/53366/

Source Science 10 August 2007: Vol. 317. no. 5839, p. 748
DOI: 10.1126/science.317.5839.748c
URL http://www.sciencemag.org.gate2.inist.fr/cgi/reprint/317/5839/748c.pdf
Letters
The Dangers of Advocacy in Science
In matters of policy, many scientists view "advocacy" as a dangerous word. In peer-reviewed literature, many
scientists practice a subtler form of advocacy in pushing their methods, results, and conclusions. Call this IMRAD
(Introduction, Methods, Results, and Discussion) advocacy: Once bold claims about a poorly tested method or
weak result are published, their sins are forgiven and they can be worked into future introductions and
discussions at will. IMRAD advocates often stretch available data, gloss over uncertainties in their evidence, and
ignore contrary results.

Divers
Source 2007. The American Journal of Bioethics 7(7):1



Bénédicte de Boischevalier                      envoi du 10 août 2007                                             - 19 -
Ce dossier est destiné exclusivement à usage privé, suivant l'article L.122-5 du code de la propriété intellectuelle.
Quelque autre utilisation que ce soit est formellement interdite. Sont également interdits le prêt, la duplication et la
copie partielle ou totale de ce dossier Tous les droits de cette oeuvre sont réservés
URL http://bioethics.net/journal/j_articles.php?aid=1288
Has the Spread of HPV Vaccine Marketing Conveyed Immunity to Common Sense?
by Glenn McGee, Summer Johnson
Approximately 20 million men and women in the U.S. are infected with human papillomavirus (HPV). For those
whose infections are not transient, genital warts are the least objectionable problems caused by several versions
of this sneaky virus, comprised of more than 200 permutations. HPV accounts for at least 65% of cervical cancer
cases. It has become a scourge for sexually active women killing hundreds of thousands worldwide, most in the
developing world, and more than 3,000 in the U.S. each year.




Bénédicte de Boischevalier                      envoi du 10 août 2007                                             - 20 -

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:10
posted:8/23/2011
language:French
pages:20